Markers of activated coagulation and their usefulness in the clinical laboratory

Clinical Chemistry

Volumn 42, Issue 5, 1996, Pages 664-669

  Tripodi, Armando ^a,b   Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE   (Italy)

Author keywords

anticoagulants; autoimmune disorders; cardiopulmonary bypass; coagulation cascade; hemostasis; peptides; systemic lupus erythematosus; thrombomodulin; thrombophilia; thrombosis

Indexed keywords

ENZYME PRECURSOR;

ANTICOAGULANT THERAPY; BLOOD CLOTTING; CLINICAL LABORATORY; DIAGNOSTIC VALUE; ENZYME ACTIVATION; ENZYME INHIBITOR COMPLEX; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; PATIENT MONITORING; REVIEW; THROMBOSIS;

EID: 0029985611     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.5.664     Document Type: Review

References (55)

1. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insight gained from studies using markers of hemostatic system activation. Blood 1987;70:343-50.
2. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanism of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
3. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a "prima ballerina" [Review]. Thromb Haemost 1995;74: 7-17.
4. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992;80:25-8.
5. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81:734-44.
6. Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: presence in factor IX concentrate and persistence in the circulation after infusion. Blood 1979;53:828-37.
7. Meade TW, Brozovic M, Chakrabarti RR, North WRS, Haines AP, Stirling Y, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii:533-7.
8. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990;76:731-6.
9. Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989;74:2007-15.
10. Aronson DL, Stevan L, Ball AP, Franza BR Jr, Fynlaison JS. Generation of the combined prothrombin activation peptide (F1.2) during the clotting of blood and plasma. J Clin Invest 1977;60: 1410-8.
11. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for F2/F1 + 2 fragment and the thrombin-antithrombin complex. Blood 1982;59:1086-97.
12. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153-9.
13. Shi Q, Ruiz JA, Perez LM, Denis RF, Sio R, Alvarez D, et al. Detection of prothrombin activation with a two-sites enzyme immunoassay for the fragment 1.2 [Abstract]. Thromb Haemost 1989;62:165.
14. Hursting MJ, Butman BT, Steiner JP, Moore BM, Plank MC, Szewczyk KM, et al. Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay. Clin Chem 1993;39:583-91.
15. Nossel HL, Yudelman Y, Canfield RE, Butler VP Jr, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974;54:43-53.
16. Nichols AB, Owen J, Kaplan KL, Sciacca RR, Canion PJ, Nossel HL. Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease. Blood 1982;60:650-4.
17. Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP Jr. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976;58:1136-44.
18. Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of Protein C activation in humans. J Clin Invest 1984;74:2033-41.
19. Gruber A, Griffin JH. Direct detection of activated Protein C in blood from human subjects. Blood 1992;79:2340-8.
20. Pelzer H, Schwarz A, Heimburger N. Determination of thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:101-6.
21. Espana F, Vincente V, Tabernero D, Scharrer I, Griffin JH. Determination of plasma Protein C inhibitor and of two activated Protein C inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990;59:593-608.
22. Espana F, Gruber A, Heeb MJ, Hanson SR, Harker LA, Griffin JH. In vivo and in vitro complexes of activated Protein C with two inhibitors in baboons. Blood 1991;77:1754-60.
23. Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, et al. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992;79:2039-47.
24. ten Cate H, Bauer KA, Levi M, Edgington TS, Subblett RD, Barzegar S, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993;92:1207-12.
25. Burrnan JF, Chung HI, Lane DA, Philippou L, Adami A, Lincoln JC. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 1994;344:1192-3.
26. Conard J, Bauer KA, Gruber A, Griffin JH, Schwarz HP, Horellou MH, et al. Normalization of markers of coagulation activation with a purified Protein C concentrate in adults with homozygous Protein C deficiency. Blood 1993;82:1159-64.
27. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after infusion of a purified factor IX concentrate. Blood 1990;76:2540-5.
28. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati F, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991;79:606-11.
29. Tripodi A, Mannucci PM. A survey of inherited thrombotic syndromes in Italy. Res Clin Lab 1989;19:67-74.
30. Mannucci PM, Tripodi A, Bottasso B, Baudo F, Finazzi G, De Stefano V, et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67:200-2.
31. Demers C, Ginsberg JS, Henderson P, Ofosu FA, Weitz JI, Blajchman MA. Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemost 1992;67: 542-4.
32. Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou MH, Samama MM, Rosenberg RD. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988;71:1418-26.
33. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Ann Intern Med 1990;112:682-98.
34. Tripodi A, Mannucci PM, Chantarangkul V, Bottasso B, Arbini A, Delia Bella S, Scorza R. Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. Br J Haematol 1993;84:670-4.
35. Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993;81: 2958-63.
36. Neri Serneri GG, Gensini GF, Abbate R, Laureano R, Parodi O. Is raised plasma fibrinopeptide A a marker of acute coronary insufficiency [Letter]? Lancet 1980;ii:982.
37. Neri Serneri GG, Gensini GF, Carnovali M, Prisco D, Rogasi PG, Casolo GC, et al. Association between time of increased fibrinopeptide levels in plasma and episodes of spontaneous angina: a controlled prospective study. Am Heart J 1987;113:672-8.
38. Theroux P, Latour JG, Leger-Gauthier C, De Lara J. Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987;75:156-62.
39. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.
40. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans: normative aging study. J Clin Invest 1987;80:1527-34.
41. Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA. Rosenberg RD. Hypercoagulability in centenarians: the paradox of successful aging. Blood 1995;85:3144-9.
42. Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol 1990;74:471-9.
43. Boneu B, Bes G, Pelzer H, Sié P, Boccalon H. D-dimers, thrombin-antithrombin III complexes and prothrombin fragments 1 + 2: diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991;65:28-32.
44. Estivals M, Pelzer H, Sié P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effect of heparin treatment. Br J Haematol 1991;78:421-4.
45. Elias A, Bonfils S, Daoud-Elias M, Gauthier B, Sié P, Boccalon H, Boneu B. Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost 1993;69:302-5.
46. DVTENOX Study Group. Markers of hemostatic activation in acute deep venous thrombosis. Evolution during the first days of treatment. Thromb Haemost 1993;70:909-14.
47. Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987;80: 1535-44.
48. Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F 1 + 2 levels. Blood 1992; 79:2034-8.
49. Mannucci PM, Bottasso B, Tripodi A. Prothrombin fragment 1 + 2 and intensity of treatment with oral anticoagulants [Letter]. Thromb Haemost 1991;66:741.
50. Li Z, Wu J, Mammen EF. Prothrombin fragment F 1 + 2 and oral anticoagulant therapy. Thromb Res 1994;75:601-7.
51. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. The effect of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemostas 1995;73:82-6.
52. Bauer KA, Barzegar S, Rosenberg RD. Influence of anticoagulants used for blood collection on plasma prothrombin fragment 1 + 2 measurements. Thromb Res 1991;63:617-28.
53. Leroy-Matheron C, Gouault-Heilmann M. Influence of conditions of blood sampling on coagulation activation markers (prothrombin fragment 1 + 2. thrombin-antithrombin complexes and D-dimers) measurements. Thromb Res 1994;74:399-407.
54. Tripodi A. Chantarangkul V, Bottasso B, Mannucci PM. Poor comparability of prothrombin fragment 1 + 2 values measured Dy two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost 1994;71:605-8.
55. Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state [Letter]. Lancet 1991;338:1079.